drugset / Trial / NCT06928246

The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis

NCT06928246

Phase 1 Recruiting 8 enrolled Daniel Kaplan Almirall, S.A. · collab
Non-randomizedSequentialOpen-labelOther

Summary

The purpose of this study is to understand cellular and molecular interactions in the skin of participants with mild-to-moderate AD, and how botulinum toxin alters these interactions.

Timeline

Start
2025-07-17
Primary completion
2026-12-15
Completion
2027-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 50 iu Other
Subject Botulinum toxin type A Protein / enzyme biologic 75 iu Other

Indications